SG11201803118WA - Therapeutic agent for breast cancer - Google Patents
Therapeutic agent for breast cancerInfo
- Publication number
- SG11201803118WA SG11201803118WA SG11201803118WA SG11201803118WA SG11201803118WA SG 11201803118W A SG11201803118W A SG 11201803118WA SG 11201803118W A SG11201803118W A SG 11201803118WA SG 11201803118W A SG11201803118W A SG 11201803118WA SG 11201803118W A SG11201803118W A SG 11201803118WA
- Authority
- SG
- Singapore
- Prior art keywords
- therapeutic agent
- breast cancer
- breast
- cancer
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015246308 | 2015-12-17 | ||
| PCT/JP2016/087349 WO2017104739A1 (en) | 2015-12-17 | 2016-12-15 | Therapeutic agent for breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803118WA true SG11201803118WA (en) | 2018-05-30 |
Family
ID=59056770
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803118WA SG11201803118WA (en) | 2015-12-17 | 2016-12-15 | Therapeutic agent for breast cancer |
| SG10201913213WA SG10201913213WA (en) | 2015-12-17 | 2016-12-15 | Therapeutic agent for breast cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913213WA SG10201913213WA (en) | 2015-12-17 | 2016-12-15 | Therapeutic agent for breast cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180303817A1 (en) |
| EP (1) | EP3391885B1 (en) |
| JP (1) | JP6858132B2 (en) |
| KR (1) | KR102486722B1 (en) |
| CN (2) | CN108367000A (en) |
| AU (1) | AU2016374441B2 (en) |
| CA (1) | CA3001969C (en) |
| ES (1) | ES2867804T3 (en) |
| IL (1) | IL258671A (en) |
| MX (1) | MX2018006329A (en) |
| RU (1) | RU2730503C2 (en) |
| SG (2) | SG11201803118WA (en) |
| WO (1) | WO2017104739A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3694513A4 (en) * | 2017-10-12 | 2021-06-30 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition comprising fgfr selective tyrosine kinase inhibitor |
| EP3777860A4 (en) | 2018-03-28 | 2021-12-15 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
| BR112022020786A2 (en) * | 2020-04-17 | 2022-11-29 | Eisai R&D Man Co Ltd | BREAST CANCER THERAPEUTIC AGENT |
| AU2021315234A1 (en) * | 2020-07-31 | 2023-01-19 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
| WO2022092085A1 (en) | 2020-10-28 | 2022-05-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Pharmaceutical composition for treating tumors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7098332B2 (en) * | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| AR094812A1 (en) * | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | DERIVED FROM MONOCYCLIC PYRIDINE AS AN FGFR INHIBITOR |
| KR102344105B1 (en) * | 2014-08-18 | 2021-12-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Salt of monocyclic pyridine derivative and crystal thereof |
-
2016
- 2016-12-15 WO PCT/JP2016/087349 patent/WO2017104739A1/en active Application Filing
- 2016-12-15 SG SG11201803118WA patent/SG11201803118WA/en unknown
- 2016-12-15 KR KR1020187014626A patent/KR102486722B1/en active IP Right Grant
- 2016-12-15 RU RU2018119102A patent/RU2730503C2/en active
- 2016-12-15 MX MX2018006329A patent/MX2018006329A/en unknown
- 2016-12-15 EP EP16875716.9A patent/EP3391885B1/en active Active
- 2016-12-15 CN CN201680068110.9A patent/CN108367000A/en active Pending
- 2016-12-15 SG SG10201913213WA patent/SG10201913213WA/en unknown
- 2016-12-15 ES ES16875716T patent/ES2867804T3/en active Active
- 2016-12-15 CA CA3001969A patent/CA3001969C/en active Active
- 2016-12-15 JP JP2017556119A patent/JP6858132B2/en active Active
- 2016-12-15 CN CN202211005176.7A patent/CN115177619A/en active Pending
- 2016-12-15 US US15/771,193 patent/US20180303817A1/en active Pending
- 2016-12-15 AU AU2016374441A patent/AU2016374441B2/en active Active
-
2018
- 2018-04-12 IL IL258671A patent/IL258671A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018119102A3 (en) | 2020-02-04 |
| CN108367000A (en) | 2018-08-03 |
| EP3391885B1 (en) | 2021-03-17 |
| RU2018119102A (en) | 2020-01-17 |
| RU2730503C2 (en) | 2020-08-24 |
| JPWO2017104739A1 (en) | 2018-10-04 |
| EP3391885A1 (en) | 2018-10-24 |
| WO2017104739A1 (en) | 2017-06-22 |
| ES2867804T3 (en) | 2021-10-20 |
| SG10201913213WA (en) | 2020-03-30 |
| KR20180094862A (en) | 2018-08-24 |
| EP3391885A4 (en) | 2019-08-28 |
| CA3001969C (en) | 2023-10-03 |
| CN115177619A (en) | 2022-10-14 |
| IL258671A (en) | 2018-06-28 |
| MX2018006329A (en) | 2018-08-29 |
| JP6858132B2 (en) | 2021-04-14 |
| AU2016374441B2 (en) | 2021-10-21 |
| AU2016374441A1 (en) | 2018-05-10 |
| BR112018010103A2 (en) | 2018-11-21 |
| US20180303817A1 (en) | 2018-10-25 |
| KR102486722B1 (en) | 2023-01-11 |
| CA3001969A1 (en) | 2017-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254705B (en) | Combination therapy for cancer | |
| ZA201702382B (en) | Combination therapy for cancer | |
| IL259017A (en) | Targeted cancer therapy | |
| IL253701A0 (en) | Therapeutic agent for bile duct cancer | |
| HK1258319A1 (en) | Cancer therapy | |
| HK1231381A1 (en) | Combination therapy for cancer | |
| IL258671A (en) | Therapeutic agent for breast cancer | |
| IL246761A0 (en) | Combination therapy for cancer | |
| IL270140B (en) | Therapeutic agent for blood cancer | |
| GB201519734D0 (en) | Cancer therapy | |
| HK1254687A1 (en) | Combination therapy for cancer | |
| GB201522433D0 (en) | Cancer treatment | |
| HRP20210383T8 (en) | Combination therapy for cancer | |
| IL257292A (en) | Therapeutic agent for biliary tract cancer | |
| SG11201801083UA (en) | Tumor therapeutic agent | |
| GB201700772D0 (en) | Cancer therapy | |
| GB201511609D0 (en) | Cancer therapy | |
| GB201511121D0 (en) | Cancer therapy | |
| GB201511120D0 (en) | Cancer therapy | |
| GB201601248D0 (en) | Cancer therapy | |
| GB201417819D0 (en) | Agents for cancer therapy | |
| GB201411884D0 (en) | Cancer therapy |